Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatio

Phase 4

Completed

• Conditions: hyperactive parathyroid glands; primary hyperparathyroidism; 10083624; 10033949

• Registration Number: NL-OMON34871
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Primary hyperparathyroidism due to a genetically confirmed MEN-1 mutation

Exclusion Criteria

No MEN-1 mutation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Clinical parameters<br /><br>2. Biochemical parameters<br /><br>3. Radiological parameters; MRI-abdomen, MRI- pituitary, bone mineral density,<br /><br>ultrasound of kidney, X-spine<br /><br>4. Safety parameters</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>CaSR expression analysis on available pathological specimens</p><br>